Researchers assigned eight rats each to a control group, a disease model group and a Tanshinone IIA group. The model and treatment groups received intramuscular methylprednisolone at 30 mg/kg/day during the first three consecutive days of each week for three weeks. Tanshinone IIA was then administered by oral gavage at 8 mg/kg/day for six weeks.

Micro-computed tomography showed that the model group had lower bone volume and bone volume fraction, higher tissue volume, and disorganized, partly cystic trabeculae. Compared with the model group, the Tanshinone IIA group had recovered bone volume, a significantly increased bone volume fraction and trabeculae tending toward an orderly arrangement. Imaging and pathology assessments were conducted on three randomly selected rats per group.

Hematoxylin and eosin staining showed denser trabeculae and reduced adipocyte infiltration in the Tanshinone IIA group than in the model group. Tartrate-resistant acid phosphatase staining showed fewer osteoclasts and weaker staining in the treated group. These findings concern changes in the experimental model and do not establish clinical efficacy in people with osteonecrosis.

Untargeted fecal metabolomics, performed with six rats per group, identified 18 differentially abundant metabolites between control and model animals and 19 between model and Tanshinone IIA animals. Xanthine, hypoxanthine, 2-oxopentanedioic acid and succinic semialdehyde were elevated in the model group and declined after Tanshinone IIA intervention.

Pathway enrichment included purine metabolism in the model comparison and 2-oxocarboxylic acid, butanoate, amino acid and related metabolic pathways in the treatment comparison. The metabolomic patterns suggested partial rather than complete normalization, with global differences between control and Tanshinone IIA animals remaining modest, based on a Q² value of 0.04. Pyruvate and glutamic acid were lower in the Tanshinone IIA group than in the model group; the authors interpreted this as potentially consistent with greater metabolic utilization, not direct proof of enhanced mitochondrial activity.

Data-independent acquisition proteomics, based on five rats per group, identified 116 differentially expressed proteins between control and model animals and 12 between model and Tanshinone IIA animals. Model-related proteins were enriched in Hippo, TGF-β and Wnt signaling pathways, while the treated comparison was primarily associated with aminoacyl-tRNA biosynthesis and lipid-related pathways.

Matched metabolomic and proteomic data identified Bmp6, Smoc2, Ihh and Enpp2 as proteins significantly correlated with differential metabolites after false-discovery-rate correction. These multi-omics findings are correlative and hypothesis-generating rather than evidence that the proteins caused the observed changes.

The study had small analytical samples, no positive drug control and no network-centrality analysis. Fecal metabolomics reflects systemic host–microbiota metabolism and may not represent local femoral-head conditions. Candidate proteins were selected through correlation analysis and prior literature rather than causal experiments, while oral administration of poorly water-soluble Tanshinone IIA may have limited exposure. Overall, the rat experiment provides preliminary evidence associating Tanshinone IIA with changes across bone structure, metabolism and protein networks, and its clinical relevance cannot be determined from the animal data alone.

Subject of Research: Multi-omics assessment of Tanshinone IIA in a rat model of steroid-induced femoral-head osteonecrosis

Article Title: Insights into potential multi-target protective effects of Tanshinone IIA in steroid-induced osteonecrosis of the femoral head: evidence from integrated metabolomics and proteomics

Article References: Li, W., Xu, N., Chai, J.-L., Zhang, B.-C., Liang, Y.-C., Li, G., & Liang, X.-Z. (2026). Insights into potential multi-target protective effects of Tanshinone IIA in steroid-induced osteonecrosis of the femoral head: evidence from integrated metabolomics and proteomics. Frontiers in Endocrinology, 17, Article 1991120. https://doi.org/10.3389/fendo.2026.1991120

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1991120

Keywords: Tanshinone IIA, osteonecrosis, femoral head, rat model, metabolomics, proteomics, bone microarchitecture, multi-omics, osteoclasts, Insights, potential, multi-target

Researchers treated collagen-induced arthritis rats with quercetin or methotrexate for 28 days, while normal rats provided a baseline. The assessment covered arthritis scores, hind-paw volume, inflammatory cytokines, bone-related measures, joint damage and Wnt3A and β-catenin expression. Compared with normal rats, the arthritic animals had higher arthritis scores, greater hind-paw swelling and elevated levels of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-17A.

The collagen-induced arthritis group also showed reduced bone mineral density, bone volume fraction, trabecular thickness and trabecular number, together with severe joint damage. According to the abstract, quercetin intervention alleviated clinical symptoms, improved bone microarchitecture, restored cytokine balance and substantially downregulated Wnt3A and β-catenin at both the messenger RNA and protein levels in the spleen and joints. The reported improvements in bone microarchitecture were comparable to those achieved with methotrexate in the experiment. Quercetin also did not induce observable hepatorenal toxicity under the study’s testing conditions.

These findings are limited to the reported rat experiment and to the outcomes described in the available abstract, which was presented as a subscription preview rather than the full article. The parallel changes in pathway expression, inflammation and bone measures support a possible mechanistic association, but they do not prove a direct causal relationship. The results therefore provide a basis for further investigation and do not demonstrate that quercetin is safe or disease-modifying in people with rheumatoid arthritis.

Subject of Research: Quercetin effects on bone erosion, inflammation and Wnt3A/β-catenin expression in collagen-induced arthritis rats

Article Title: Quercetin ameliorates rheumatoid arthritis-associated bone erosion via inhibiting the Wnt3a/β-catenin signaling axis

Article References: Shen, T., Liang, R., Liang, M., Guo, Q., & Pang, Q. (2026). Quercetin ameliorates rheumatoid arthritis-associated bone erosion via inhibiting the Wnt3a/β-catenin signaling axis. Molecular Biology Reports, 53(1), Article 1575. https://doi.org/10.1007/s11033-026-12740-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12740-8

Keywords: quercetin, collagen-induced arthritis, bone erosion, bone microarchitecture, Wnt3A, β-catenin, rheumatoid arthritis, inflammation, methotrexate, animal study, ameliorates, rheumatoid

In vitro, they stimulated bone marrow-derived macrophages with RANKL to induce osteoclast differentiation, with or without Bruceine D. Treatment suppressed the formation of multinucleated osteoclasts in a dose-dependent manner. The effective concentrations were not reported as cytotoxic.

TRAP staining was used to assess osteoclast formation, while quantitative reverse-transcription PCR and western blotting were used to examine gene and protein expression. Multiple cellular measurements were consistent with inhibited osteoclast development. It also reduced the cells’ bone-resorption activity.

At the molecular level, the compound attenuated STAT3 and NF-κB signaling without affecting the tested MAPK and AKT pathways. The reduced signaling was associated with downregulation of NFATc1, a key transcription factor in osteoclastogenesis, leading the authors to identify the STAT3/NF-κB/NFATc1 axis as the mechanism implicated in the observed effects. The researchers next evaluated Bruceine D in an ovariectomy model of osteoporosis.

Ovariectomy produces estrogen deficiency and bone loss in mice, allowing the investigators to examine protection against deterioration of bone microarchitecture. Bruceine D treatment markedly alleviated trabecular bone loss, with improved bone-microarchitecture parameters reported in treated animals. These results show a protective effect in this mouse model and align with the compound’s inhibition of osteoclast formation and activity observed in cultured cells.

The evidence is limited to laboratory cultures and an ovariectomized mouse model, so the findings do not establish that Bruceine D is safe or effective for treating postmenopausal osteoporosis in humans. The supplied study abstract also does not provide the numerical concentrations, treatment schedules or effect sizes needed to assess the magnitude and reproducibility of the reported responses. Within those limits, the study provides convergent cellular, molecular and animal evidence that Bruceine D can suppress osteoclastogenesis and reduce estrogen-deficiency-associated trabecular bone loss under experimental conditions.

Subject of Research: Preclinical evaluation of Bruceine D for suppressing osteoclast formation and protecting against estrogen-deficiency-associated bone loss

Article Title: Bruceine D suppressed osteoclast formation via STAT3/NF-κB/NFATc1 signaling and protected postmenopausal osteoporosis

Article References: Lin, S., Yuan, Q., Yao, X., & Nie, X. (2026). Bruceine D suppressed osteoclast formation via STAT3/NF-κB/NFATc1 signaling and protected postmenopausal osteoporosis. Molecular Biology Reports, 53(1), Article 1508. https://doi.org/10.1007/s11033-026-12677-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12677-y

Keywords: Bruceine D, osteoclast formation, osteoclastogenesis, bone resorption, postmenopausal osteoporosis, ovariectomy model, STAT3 signaling, NF-κB signaling, NFATc1, bone microarchitecture, preclinical research, Bruceine

The work, published in Frontiers in Medical Engineering by Peter T. Shyu, Samuel T. Robinson, and X. Edward Guo, builds on the lab’s previous demonstration that time-lapse microCT imaging can quantify modeling and remodeling across bone microstructure. The new paper is a technical deep dive into the method of voxel-tracking, a computational approach that examines the sequence of bone events at each three-dimensional coordinate over an experimental timeline. The distinction the technique draws is fundamental to bone biology. Remodeling is bone formation and resorption coupled in space and time, carried out by basic multicellular units in which osteoclasts resorb bone and leave behind a scalloped surface, followed by a reversal phase that allows osteoblasts to form bone at the previously resorbed locations. Modeling, by contrast, is uncoupled: independent formation is called anabolic modeling, while independent resorption is called catabolic modeling. Whether these processes are coupled or uncoupled determines how bone adapts, and in metabolic bone diseases like osteoporosis the balance tips toward resorption, degrading bone mass, architecture, and strength.

Traditional methods for studying these dynamics have relied on 2D dynamic histomorphometry, in which multiple fluorochromes that chelate to calcium in mineralizing bone are administered at separated time intervals, while bone resorption is measured only indirectly. The approach comes with well-known technical difficulties: subjectivity in distinguishing smooth and scalloped bone cement lines, overlapping spectra from multiple fluorochrome labels, lack of labels compatible with osteoporosis therapeutics, and the need for ex vivo processing of 2D samples. Computed tomography has changed the landscape. Using image registration, the accurate and longitudinal identification of bone formation and resorption was first shown in the rat tibia in 2004, and the technique was subsequently developed to quantify dynamics in mouse tail vertebral trabecular and cortical bone and tibial cortical bone. But few studies have specifically quantified remodeling as bone formation following bone resorption at a specific location. The Columbia group’s method is designed to do exactly that, directly assessing longitudinal 3D modeling and remodeling across the bone microstructure.

The experimental system is elegant in its precision. The researchers applied mechanical loading to 16-week-old mice 5 consecutive days per week for 5 weeks, loading the right tibia by axial compression while the left tibia served as an internal, nonloaded control. A standard load frame applied a preload of 1 N compression for 4 minutes, followed by a haversine waveform between 1 N and 9 N compression for 100 cycles at 2 Hz. Critically, in vivo microCT imaging of the tibia began 2 weeks before the start of mechanical loading, with weekly follow-up imaging, so that the baseline state of the bone was fully characterized before any loading stimulus was applied. Scanning parameters included 55 kVp energy, 145 µA intensity, 300 ms integration time, and no frame averaging, with images reconstructed at 5 µm isotropic voxel size. Each tibia scan covered a 3.84 mm region in length, starting from the proximal growth plate and extending distally, with a scan time of 13.3 minutes per tibia under isoflurane anesthesia.

The computational heart of the method is the image registration and voxel-tracking pipeline. Full-resolution 16-bit grayscale images of extracted trabecular and cortical bone regions were registered and transformed to a common 3D position using Scanco Image Processing Language algorithms. To minimize bias from interpolation of voxel values during image transformation, the first pair of weekly microCT images were transformed to their midpoint, so that every weekly image is subject to similar interpolation effects. Images were first aligned by center of mass, followed by 3D rigid registration using a downhill simplex method to maximize the normalized correlation coefficient, with registration performed at three downscaling levels to avoid local maxima. Because the trabecular bone shifts distally over time due to the continually active growth plate in mice of this age, a two-step registration scheme was used: first a mask including the whole bone, followed by a trabecular bone-specific mask. Cortical bone regions required only one step using a mask of the entire cortical bone.

After registration, a Gaussian filter was applied to both reference and follow-up images to reduce noise, and images were segmented by applying global threshold values of 360 and 400 per mille for trabecular and cortical bone, respectively. The reference image was then subtracted from the follow-up image to identify bone formed and bone resorbed, which were saved as separate images. To capture bone formation at its earliest stage, as osteoid is first secreted and then mineralized over time, voxels with values greater than 75% of the global threshold value after image subtraction were also classified as formed bone. The resulting images were further filtered by removing clusters of less than 15 voxels, considered likely to be noise. Masking algorithms ensured that voxels classified as bone formed were labeled as bone in the follow-up image and as background in the reference image, and vice versa for voxels classified as bone resorbed. The segmented reference and follow-up images were added together to identify voxels labeled as bone in both time points, resulting in a constant bone image, and the three images were concatenated to generate weekly transition images with each voxel labeled with the bone event that occurred.

Quantifying bone volume changes was done by tracking the events at the voxel-level over the experimental timeline. Cut images were converted to text files listing each voxel’s coordinate and a value designating its bone adaptation event — formation, resorption, constant bone, or background — using a custom C-based program, and a custom MATLAB script was used to quantify bone volume changes at each voxel. The sequence of bone events at each voxel was characterized by applying a moving window to count the bone events at that voxel. With 5 weeks of mechanical loading, catabolic modeling can be quantified at the first 3 time points because week 3 is the last week with 2 follow-up images available to distinguish catabolic modeling. Bone volume changes, formation, and resorption events were normalized to their respective values at baseline prior to the start of loading, while modeling and remodeling values were normalized to the baseline bone volume.

The results reveal striking site-specific differences in how bone responds to mechanical loading. In the trabecular bone of control limbs, BV/TV decreased more drastically over time in wildtype mice due to greater levels of bone resorption and a decline in bone formation compared to SOST knockout mice. Loading increased wildtype BV/TV relative to control limbs due to elevated levels of bone formation, while the SOST knockout response was more attenuated and driven by a slight trend of decreased bone resorption. After further classification of formation and resorption into modeling and remodeling events, loading was observed to stimulate anabolic modeling and remodeling and reduce catabolic modeling throughout the course of loading in wildtype mice. The accumulated bone volumes by anabolic modeling and remodeling in wildtype mice increased after loading, and these values were greater than in SOST knockout mice. Catabolic modeling bone volume changes were decreased after loading in wildtype mice, particularly due to an early response in week 1, while the response in SOST knockout mice was more attenuated.

Cortical bone told a more nuanced story. Periosteal bone volumes increased more robustly due to loading, resulting in increases in overall cortical bone volume to levels above baseline for both genotypes. Endosteal bone volumes remained relatively stable over the course of loading, with a trend for an early increase in wildtype endosteal bone volumes that then decreased by week 5. Cortical formation peaked by week 2 for wildtype mice and then decreased with continued loading, while SOST knockout mice showed a more level formation response. The overall cortical bone response was dominated by modeling rather than remodeling. Loading affected wildtype modeling and remodeling from the onset of loading, particularly with an early increase in remodeling through week 2, and SOST knockout mice showed a similar but reduced response in accumulated changes of modeled and remodeled bone. In control SOST knockout limbs, there was an overall increase in modeling and remodeling compared to wildtype bone over time.

The implications reach beyond the mouse tibia. Sclerostin, encoded by the SOST gene, is the target of romosozumab, a humanized antibody approved for osteoporosis treatment with time-dependent effects on trabecular and cortical bone. Understanding how SOST depletion alters the coupling of formation and resorption under mechanical load provides mechanistic insight into how such therapies interact with exercise, a promising noninvasive treatment option for improving bone strength. The technique’s versatility extends to clinical imaging: time-lapse HR-pQCT with an effective dose of 3–4 µSv is increasingly used to evaluate human bone turnover, and the voxel-tracking approach could be adapted to suit different subjects and regions of interest. The authors note that longitudinal real-time subject-specific finite element analysis can be incorporated and combined with other segmentation techniques to label the trabecular microarchitecture by individual plates and rods. As the global burden of fractures continues to grow — affecting an estimated 1 in 2 women and 1 in 5 men over age 50 — techniques that directly assess modeling and remodeling dynamics in space and time will provide critical inputs for computational models of bone adaptation and disease progression, and function as a valuable tool for analyzing the long-term effects of therapies for bone diseases.

Subject of Research: In Vivo quantification of 4D modeling and remodeling in trabecular and cortical bone microstructure

Article Title: In Vivo quantification of 4D modeling and remodeling in trabecular and cortical bone microstructure

Article References: Shyu, P. T., Robinson, S. T., & Guo, X. E. (2025). In Vivo quantification of 4D modeling and remodeling in trabecular and cortical bone microstructure. Frontiers in Medical Engineering, 3, Article 1547895. https://doi.org/10.3389/fmede.2025.1547895

Image Credits: AI Generated

DOI: 10.3389/fmede.2025.1547895

Keywords: Vivo, quantification, modeling, remodeling, trabecular, cortical, bone, microstructure, scientific research

The research, led by Faiz Qamar under the supervision of Manju Sharma, focused on a well-established animal model of type 2 diabetes. Female Wistar rats were first fed a high-fat diet and then given a single intraperitoneal dose of streptozotocin at 35 milligrams per kilogram, a protocol that reproduces the insulin resistance and pancreatic beta-cell dysfunction characteristic of human type 2 diabetes. Once diabetes was established, the animals were divided into treatment groups receiving oral therapy for twelve weeks: canagliflozin alone at either 10 or 20 milligrams per kilogram, fenugreek seed extract at 400 milligrams per kilogram, canagliflozin at 10 milligrams per kilogram combined with metformin at 200 milligrams per kilogram, or the full triple combination of canagliflozin, metformin, and fenugreek seed extract at the same doses.

What makes this study technically significant is the breadth of skeletal endpoints the investigators measured. At the end of the treatment period, they assessed serum insulin and glycated haemoglobin, or HbA1c, as markers of long-term glycaemic control. For bone health, they turned to tartrate-resistant acid phosphatase, or TRAP, a serum enzyme released by osteoclasts, the cells responsible for breaking down bone. Elevated TRAP activity signals accelerated bone resorption. They also measured urinary calcium excretion, an indicator of calcium loss from the skeleton, and used micro-computed tomography, or micro-CT, to visualize and quantify the three-dimensional trabecular architecture of the femur, the spongy internal scaffolding that gives bone its strength while remaining light.

The untreated diabetic animals showed exactly the pattern of deterioration that clinicians fear in patients with long-standing diabetes. Their femoral trabecular bone exhibited marked reductions in bone volume fraction, trabecular thickness, trabecular number, and connectivity density, the last being a measure of how well the internal struts of bone are connected to one another and therefore how effectively the structure distributes mechanical load. At the same time, trabecular separation, the average gap between bone struts, increased, as did the structural model index, or SMI, a parameter that shifts toward plate-like and rod-like geometry as bone becomes weaker and more fracture-prone. Histological examination of the bone tissue confirmed these micro-CT findings, painting a consistent picture of diabetes-driven skeletal fragility.

Against this backdrop, the treatment results were striking. By week twelve, the triple combination of canagliflozin, metformin, and fenugreek seed extract had reduced fasting blood glucose by approximately 57.8 percent compared with diabetic control animals, while HbA1c fell by roughly 47.4 percent. These are substantial metabolic improvements, but the skeletal data were equally compelling. Serum TRAP activity, the biochemical signature of osteoclast-driven bone breakdown, declined by about 26.1 percent in the combination group, and urinary calcium excretion dropped by approximately 31.4 percent, suggesting that less calcium was being leached from the skeleton and lost through the kidneys.

Canagliflozin itself deserves particular attention in this context. The drug belongs to the sodium-glucose co-transporter 2, or SGLT2, inhibitor class, which works by blocking glucose reabsorption in the proximal tubule of the kidney, forcing excess glucose to be excreted in the urine. While the class has proven cardiovascular and renal benefits, some clinical evidence, including analyses from the CANVAS trial program, has raised questions about fracture risk with canagliflozin, making its skeletal profile a subject of genuine scientific debate. The new findings suggest that, at least in this experimental model of diabetic osteopathy, canagliflozin-based regimens attenuated rather than worsened trabecular deterioration, a result the authors argue supports further investigation of the drug’s skeletal effects and the mechanisms underlying them.

Metformin, the second pharmaceutical component of the combination, brings a different mechanism to the table. It acts primarily through activation of AMP-activated protein kinase, or AMPK, a cellular energy sensor that influences glucose production in the liver and insulin sensitivity in peripheral tissues. Interestingly, metformin has also been implicated in bone biology, with studies suggesting it may modulate the balance between osteoblasts, the bone-forming cells, and osteoclasts, the bone-resorbing cells. By improving insulin signalling, metformin may indirectly support bone, since insulin itself has anabolic effects on the skeleton, stimulating osteoblast activity and bone formation. The interplay between glycaemic control and bone metabolism is therefore not merely coincidental but mechanistically intertwined.

The third ingredient, fenugreek seed extract, is derived from Trigonella foenum-graecum, an herb with a long history in traditional medicine systems across South Asia and the Middle East. Modern research has identified multiple bioactive compounds in fenugreek, including the steroidal saponin diosgenin, which has been shown in cell studies to influence the Wnt/beta-catenin signalling pathway, a key regulator of osteoblast proliferation and differentiation. Fenugreek has also demonstrated antidiabetic properties in numerous preclinical and some clinical studies, thought to arise from its fibre content, saponins, and 4-hydroxyisoleucine, an amino acid with insulin-sensitizing activity. Including a botanical extract alongside two established pharmaceuticals reflects a growing interest in adjunctive phytotherapy for metabolic disease, though the authors are careful to frame the results as preclinical evidence requiring further study rather than a prescription for human use.

The significance of the study lies partly in its systematic comparison of monotherapy and combination approaches. Canagliflozin alone, at both doses tested, along with fenugreek seed extract and the dual canagliflozin-metformin combination, all attenuated the diabetes-associated skeletal alterations to varying degrees, but the triple regimen produced the most pronounced improvements in both metabolic and microarchitectural parameters. This dose-response-like gradient across regimens hints at possible additive or synergistic effects among the three agents, whether through complementary mechanisms of glucose lowering, reduced glucotoxicity in bone cells, or direct effects on osteoblast and osteoclast activity. The consistency between the biochemical markers, the micro-CT quantification, and the histological observations strengthens the internal validity of the findings, since each independent line of evidence points in the same direction.

For the millions of people living with type 2 diabetes, the spectre of skeletal fragility is an underappreciated burden. Diabetic bone disease differs from ordinary osteoporosis in that bone mineral density may appear normal or even elevated on standard scans, yet fracture risk remains substantially increased, a paradox attributed to impaired bone quality, accumulation of advanced glycation end-products that stiffen the collagen matrix, and disrupted remodelling. The Jamia Hamdard team’s work adds an important piece to this puzzle by demonstrating that aggressive glycaemic management with a rational drug combination can preserve trabecular microarchitecture in a model that closely mimics the human disease. While the results must be replicated and extended, including studies of bone strength and fracture mechanics, and ultimately clinical trials in patients, the message is clear: the drugs we choose to control diabetes may also shape the skeleton, and the right combinations could turn that influence to the patient’s advantage. The study was approved by the Institutional Animal Ethics Committee at Jamia Hamdard and conducted in compliance with Indian regulatory guidelines, with the authors reporting no conflicts of interest.

Subject of Research: Effects of canagliflozin, metformin, and fenugreek seed extract combinations on bone health in experimental diabetes

Article Title: Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy

Article References: Qamar, F., Sultana, S., Vaseem, M., Ahmad, T., & Sharma, M. (2026). Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy. 3 Biotech, 16(10), Article 446. https://doi.org/10.1007/s13205-026-05079-1

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05079-1

Keywords: diabetes, diabetic osteopathy, canagliflozin, metformin, fenugreek seed extract, SGLT2 inhibitors, bone microarchitecture, micro-CT, trabecular bone, streptozotocin, rat model, HbA1c

A new study published in Archives of Osteoporosis now offers the most detailed portrait yet of what happens to bone in the immediate aftermath of a cerebral ischemic event. In the baseline analysis of the Post-stroke Osteopathy study, a team led by researchers at the Medical University of Innsbruck in Austria combined high-resolution peripheral quantitative computed tomography, or HR-pQCT, with an extensive panel of biochemical bone markers in a cohort of acute stroke and TIA patients. According to the investigators, this is the largest cohort of ischemic stroke or TIA patients ever examined prospectively with HR-pQCT and the first study anywhere to correlate bone biomarkers with high-resolution imaging parameters in this clinical setting.

The imaging technique at the heart of the study represents a major leap beyond conventional bone assessment. Dual-energy X-ray absorptiometry, the workhorse of osteoporosis screening, measures bone mass in two dimensions and misses critical information about bone quality. HR-pQCT, by contrast, resolves the three-dimensional microarchitecture of cortical and trabecular bone at peripheral sites such as the distal radius and distal tibia with an impressive 61-micrometer voxel size and very low radiation exposure. This matters because bone strength depends not merely on how much mineral bone contains but on its morphology and microstructure, a fact convincingly established by large international consortia showing that cortical and trabecular microarchitecture independently predict fracture risk in older women and men.

In the study, 122 participants were enrolled between March 2021 and May 2022 at the University Hospital Innsbruck as a pilot sub-study of the ongoing STROKE-CARD Registry. Of these, 116 underwent baseline HR-pQCT imaging of all four extremities within days of their event, with a median age of 71.5 years and 26.7 percent women. Neurological deficits were predominantly mild, reflected by a median National Institutes of Health Stroke Scale score of 2, and scans were performed on average 5.4 days after admission. Blood samples for biomarker analysis were drawn in 62 patients a mean of 3.0 days after admission and analyzed using validated enzyme-linked immunosorbent assays for osteocalcin, C-telopeptide of crosslinked collagen type 1, sclerostin, osteoprotegerin, soluble RANKL, and periostin.

The imaging results revealed clear patterns. Women in the cohort had lower total, cortical, and trabecular volumetric bone mineral density, along with lower values for nearly every other HR-pQCT parameter, in both the upper and lower extremities. This finding mirrors what has been documented in healthy reference populations, suggesting that stroke patients retain normal sex-based differences in bone structure. Increasing age was associated with lower total and cortical volumetric bone mineral density, but intriguingly, trabecular parameters showed no relationship with age in this cohort, a dissociation the authors suggest may be linked to higher sclerostin levels in elderly patients, which correlated with stable trabecular architecture.

Lifestyle and metabolic factors left their own signatures on the skeleton. Active or former smokers had lower total and trabecular volumetric bone mineral density in the tibia but not in the radius, consistent with prior evidence that smoking exerts a particularly strong influence on the trabecular compartment. Higher body mass index was associated with greater cortical and trabecular bone areas and higher trabecular density, especially in the radius. The weaker BMI effect in the tibia, a weight-bearing bone where mechanical loading might be expected to matter most, prompted the authors to argue that BMI captures complex systemic processes rather than simple mechanical loading, with detrimental lipotoxic and metabolic pathways potentially counteracting the localized benefits of extra weight at the lower limb.

The biomarker correlations provided some of the most novel insights of the analysis. Sclerostin, a protein secreted by osteocytes that suppresses bone formation, showed a positive correlation with trabecular HR-pQCT parameters, including trabecular volumetric bone mineral density in both the radius and the tibia, an association never before examined in a stroke or TIA population. Higher osteoprotegerin levels were linked to lower cortical area and thickness, echoing findings from the STRAMBO study of men, which similarly showed that elevated osteoprotegerin selectively affects the cortical rather than the trabecular compartment. Osteocalcin, a marker of bone turnover, correlated negatively with total volumetric bone mineral density and cortical thickness in the radius, in line with prior studies linking higher osteocalcin to increased bone turnover and skeletal fragility.

Notably, several traditional cardiovascular risk factors failed to leave any measurable trace on the skeleton in this cohort. No correlation was found between any HR-pQCT parameter and diabetes mellitus, blood pressure, or dyslipidemia, and neither stroke severity at admission nor stroke etiology, classified according to the TOAST criteria, was associated with imaging or biomarker outcomes. When the 17 patients with TIA were excluded to focus on confirmed strokes, the findings remained unchanged, reinforcing the robustness of the observed patterns. Overall, the biochemical markers exerted more influence on bone parameters in the radius than in the tibia, an asymmetry that future longitudinal follow-up may help explain.

The authors are candid about the limitations of their work. The cohort was recruited at a single center, all participants were of European descent, women were underrepresented owing to eligibility criteria such as the exclusion of patients with known osteoporosis, and HR-pQCT measurements were confined to peripheral skeletal sites that may not fully reflect changes in the axial skeleton. The acute phase after stroke may itself perturb biomarker levels, baseline blood sampling was not feasible in all patients, and the exploratory correlation analyses, involving many comparisons without formal adjustment for multiple testing, warrant cautious interpretation. The absence of an in-house, age-matched healthy control group further means the baseline findings describe the absolute bone status of acute patients rather than stroke-specific deviations.

Even so, the study establishes a crucial foundation. By pairing the finest available in vivo images of bone microstructure with a comprehensive biochemical profile gathered within days of a cerebral ischemic event, the Innsbruck team has created the reference point against which future bone loss after stroke can be measured. The prospective design of the Post-stroke Osteopathy study, with follow-up imaging and blood sampling at 3, 6, and 12 months, promises to chart the trajectory of skeletal deterioration and to clarify whether the biomarker signals identified at baseline predict which patients will go on to suffer the devastating fractures that raise mortality and erode quality of life after stroke. If those predictions hold, routine bone microarchitecture screening and early targeted intervention could become standard components of post-stroke care.

Subject of Research: Bone microarchitecture and biomarker characteristics in patients after ischemic stroke or transient ischemic attack assessed with HR-pQCT imaging

Article Title: High-resolution peripheral quantitative computed tomography imaging and bone biomarker characteristics of patients with ischemic stroke or transient ischemic attack—baseline analysis of the Post-stroke Osteopathy study

Article References: Dejakum, B., Bereiter-Payr, J., Felicetti, S., Moelgg, K., Karisik, A., Degenhart, G., Toell, T., Boehme, C., Mayer-Suess, L., Pechlaner, R., Liphardt, A.-M., Berg, G., Schett, G., Kiechl, S., & Knoflach, M. (2026). High-resolution peripheral quantitative computed tomography imaging and bone biomarker characteristics of patients with ischemic stroke or transient ischemic attack—baseline analysis of the Post-stroke Osteopathy study. Archives of Osteoporosis, 21(1), Article 134. https://doi.org/10.1007/s11657-026-01767-w

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01767-w

Keywords: ischemic stroke, transient ischemic attack, HR-pQCT, bone microarchitecture, post-stroke osteopathy, bone biomarkers, osteoporosis, fracture risk, sclerostin, osteoprotegerin, osteocalcin, volumetric bone mineral density